AtriCure Inc
$ 34.77
-0.52%
20 Jul - close price
- Market Cap 1,760,786,000 USD
- Current Price $ 34.77
- High / Low $ 35.45 / 34.47
- Stock P/E N/A
- Book Value 9.71
- EPS -0.10
- Next Earning Report 2026-07-23
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA N/A %
- ROE -0.01 %
- 52 Week High 43.18
- 52 Week Low 25.36
About
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States, Europe, Asia, and internationally. The company is headquartered in Mason, Ohio.
Analyst Target Price
$47.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-05 | 2026-02-17 | 2025-10-29 | 2025-07-29 | 2025-04-29 | 2025-02-12 | 2024-10-29 | 2024-07-30 | 2024-05-01 | 2024-02-15 | 2023-11-01 | 2023-07-25 |
| Reported EPS | 0.0022 | 0.06 | -0.01 | -0.02 | -0.14 | -0.08 | -0.17 | -0.17 | -0.25 | -0.21 | -0.2 | -0.12 |
| Estimated EPS | -0.06 | -0.04 | -0.12 | -0.16 | -0.22 | -0.1488 | -0.2 | -0.17 | -0.23 | -0.23 | -0.31 | -0.31 |
| Surprise | 0.0622 | 0.1 | 0.11 | 0.14 | 0.08 | 0.0688 | 0.03 | 0 | -0.02 | 0.02 | 0.11 | 0.19 |
| Surprise Percentage | 103.6667% | 250% | 91.6667% | 87.5% | 36.3636% | 46.2366% | 15% | 0% | -8.6957% | 8.6957% | 35.4839% | 61.2903% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-07-23 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.03 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ATRC
2026-07-21 09:11:32
Citizens has reaffirmed its Market Outperform rating and $52.00 price target for AtriCure Inc. (NASDAQ:ATRC), citing an expected 11% year-over-year sales growth in fiscal 2026, driven by new product launches and consistent product iteration. The company's strong revenue growth has been led by its Pain Management, Open Ablation, and AtriClip franchises, with analysts predicting profitability this year. Recent FDA clearance for a competing product, Edwards Lifesciences' ECLIPTIS Left Atrial Appendage Exclusion System, is noted as a potential factor for AtriCure's U.S. clip business.
2026-07-20 16:11:32
This article summarizes AtriCure's (ATRC) proxy filing for its 2026 Annual Meeting, scheduled virtually for May 18, 2026. Shareholders will vote on director elections, auditor ratification, amendments to equity plans, and executive compensation, with the Board recommending approval for all proposals. The Board's composition and corporate governance practices, including diversity initiatives and committee structures, are also highlighted.
2026-07-17 06:32:00
This article from Stock Traders Daily analyzes Atricure Inc. (NASDAQ: ATRC) using AI models to provide trading strategies and multi-timeframe signal analysis. It highlights strong near and mid-term sentiment but a weak long-term outlook for ATRC, with no clear price positioning signal identified. The analysis also reveals compelling upside potential as no resistance levels remain above the current price.
2026-07-14 16:11:32
Needham has reiterated its Buy rating for AtriCure (ATRC.US) and maintained a target price of $45. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
2026-07-14 14:11:26
Needham has initiated coverage on AtriCure (ATRC.US) with a Buy rating and set a price target of $45. This new rating suggests a positive outlook for the company's stock performance. Investors will likely watch how ATRC.US reacts to this new analyst coverage.
2026-07-12 15:39:10
AtriCure's (ATRC) Investor Day 2025 focused on the company's strategic vision to eradicate complex atrial fibrillation and post-operative pain, targeting over $10 billion in global markets. The company aims for $1 billion in revenue by 2030, driven by leadership in surgical AFib treatment, continuous product innovation, and significant investments in clinical trials. Financial guidance reaffirms targets for double-digit revenue growth, positive adjusted EBITDA, and robust free cash flow conversion by the decade's end.
